The end of the transition period is imminent. How can clinical trial sponsors and CROs ease the transition to CTIS? Soon, the one-year transition period …
AbbVie Announces Submission of Supplemental New Drug Application to US FDA for Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy – …
Last month, during the Air China Cargo exhibition in Shanghai, Brussels Airport and their cargo community won the award for “IT solution of the year” …
Invivoscribe Technologies, Inc. announced today that they have submitted to Japan’s Pharmaceutical and Medical Devices Agency (PMDA) and the US Food and Drug Administration (FDA) …
VivaGel BV stands to be the first and only product approved for the prevention of recurrent BV Australian pharma giant Starpharma today announced that its …
Outline planning permission application for expansion of the Hoeford Point site now approved. Wickham Laboratories Holdings, owner of Wickham Laboratories Ltd, today announces approval of …
Elpis BioMed Ltd (Elpis), a University of Cambridge spin-out, applying its disruptive and proprietary “direct cell reprogramming” platform to produce pure, mature and highly consistent …
Stijn Lagaert at LC Patents explains how The European Union member states provide supplementary protection certificates, which may extend the patent life of certain human and veterinary pharmaceuticals for up to five years.
IPI was established by professionals with over 30 years of experience in the Pharmaceutical and Life sciences publishing sectors. Peer-Reviewed, Contemporary, Authoritative
